Patricia Danzon of the Wharton School commented on drug companies’ hesitance to produce new medications. “Bringing a new drug to market requires getting FDA approval and that requires doing clinical trials,” she said. “That’s a significant investment, and companies, unsurprisingly, are not willing to do that unless they can get a patent and be the sole supplier of that drug for at least some period of time.”